- Home
- FULC vs KRRO Comparison
FULC vs KRRO Comparison
Compare FULC & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- KRRO
- Stock Information
- Founded
- FULC 2015
- KRRO 2014
- Country
- FULC United States
- KRRO United States
- Employees
- FULC N/A
- KRRO N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- FULC Health Care
- KRRO Health Care
- Exchange
- FULC Nasdaq
- KRRO Nasdaq
- Market Cap
- FULC 210.9M
- KRRO 209.6M
- IPO Year
- FULC 2019
- KRRO 2019
- Fundamental
- Price
- FULC $2.90
- KRRO $17.41
- Analyst Decision
- FULC Hold
- KRRO Strong Buy
- Analyst Count
- FULC 8
- KRRO 7
- Target Price
- FULC $6.57
- KRRO $132.17
- AVG Volume (30 Days)
- FULC 427.9K
- KRRO 92.3K
- Earning Date
- FULC 05-12-2025
- KRRO 03-18-2025
- Dividend Yield
- FULC N/A
- KRRO N/A
- EPS Growth
- FULC N/A
- KRRO N/A
- EPS
- FULC N/A
- KRRO N/A
- Revenue
- FULC $80,000,000.00
- KRRO $2,271,000.00
- Revenue This Year
- FULC N/A
- KRRO N/A
- Revenue Next Year
- FULC N/A
- KRRO N/A
- P/E Ratio
- FULC N/A
- KRRO N/A
- Revenue Growth
- FULC 2752.05
- KRRO N/A
- 52 Week Low
- FULC $2.78
- KRRO $15.21
- 52 Week High
- FULC $10.13
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- FULC 37.74
- KRRO 30.45
- Support Level
- FULC $3.00
- KRRO $16.78
- Resistance Level
- FULC $3.35
- KRRO $25.25
- Average True Range (ATR)
- FULC 0.18
- KRRO 2.92
- MACD
- FULC 0.02
- KRRO -0.25
- Stochastic Oscillator
- FULC 24.78
- KRRO 16.57
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.